Neovasc Announces Case Series of First U.S. Reducer Implants
Published In Peer-Reviewed Journal VANCOUVER and MINNEAPOLIS, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN)
Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system
Jürgen Kuschyk1, Peter Falk2, Thomas Demming2, Oliver Marx3, Deborah Morley4, Ishu Rao4, and Daniel Burkhoff5* 11st Department of Medicine - Cardiology, University Medical Centre Mannheim,
Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report
Daniele Masarone1*, Andrea Petraio2, Antonio Fiorentino3, Santo Dellegrottaglie4,5, Fabio Valente1, Ernesto Ammendola1, Gerardo Nigro6 and Giuseppe Pacileo1 1Heart Failure Unit, Department of Cardiology, AORN dei Colli, Monaldi Hospital, Naples, Italy 2Heart Transplant Unit,